<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629873</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-Chi-BEAC-HSCT</org_study_id>
    <nct_id>NCT03629873</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects</brief_title>
  <official_title>A Phase 2 Study Evaluating Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, multi-center, open study to evaluating efficacy and safety of Chi-BEAC
      combining with auto-HSCT to treat aggressive lymphoma Subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>2 years after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission</measure>
    <time_frame>3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of hematopoietic reconstitution</measure>
    <time_frame>15 days, 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Peripheral T Cell Lymphoma</condition>
  <condition>Double-hit Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m^2 IVD d-6; Etoposide 150mg/m^2/d qd IVD d-5~-2; Cytarabine 150mg/m^2 q12h IVD d-5~-2; Cyclophosphamide 1.0g/m^2/d qd IVD d-5~-2</description>
    <other_name>Carmustine</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Autologous hematopoeitic stem cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aggressive lymphoma subjects: diffuse large B cell lymphoma confirmed by
             immunohistochemistry and aaIPI≥3; double-hit lymphoma, as first-line or second-line
             consolidation therapy; peripheral T-cell lymphoma except ALK-positive type, as
             first-line or second-line consolidation therapy; mantle cell lymphoma, as first-line
             or second-line consolidation therapy.

          2. Adequate organ system function including:

             Creatinine clearance rate ≥ 80ml/min and creatinine &lt; 160μmol/L ALT/AST ≤ 2 upper
             limit of normal Total Bilirubin &lt; 2 upper limit of normal FEV1、FVC and DLCO ≥ 50%
             predictive value Left ventricular ejection fraction ≥ 50% No Symptomatic arrhythmia

          3. Age 18-60 years, male and female

          4. ECOG score 0-1

          5. Number of neutrophil ≥ 1.5×10^9/L, number of platelet ≥ 70×10^9/L, concentration of
             hemoglobin ≥ 90g/L, number of CD34+ cells ≥ 2.0×10^6/kg

          6. Expected survival ≥ 12 weeks

          7. Volunteered to participate in this study and signed informed consent

        Exclusion Criteria:

          1. Have evidence of CNS lymphoma

          2. Relapse after autologous hematopoietic stem cell transplantation

          3. Active hepatitis B or hepatitis C virus infection

          4. Severe active infection

          5. HIV-infected persons

          6. Liver cirrhosis or hepatic fibrosis

          7. QTc &gt; 500ms

          8. Have mental disorder or unable to sign informed consent

          9. History of drug abuse and intemperance

         10. Women who are pregnant or lactating or have breeding intent

         11. The investigators believe that any increase in the risk of the subject or interference
             with the results of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Xu, Ph.D.</last_name>
    <phone>+86-25-68302182</phone>
    <email>xuwei10000@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematological Department, People's Hospital of Jiangsu Province</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Xu, Ph.D.</last_name>
      <phone>+86-2568302182</phone>
      <email>xuwei10000@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

